Incorporation of SHCBP1 into ceRNA and lactylation–associated regulatory networks has further enhanced its value for identifying subgroups of high-risk breast cancer patients who are less responsive to therapy [75,76]. This evidence concerns the gene SHCBP1 and breast carcinoma.